Clinical Strategies to Address Patients' Concerns in Osteoporosis Management with Bisphosphonates

References

• . US Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general. http://www.surgeongeneral.gov/library/bonehealth/. Accessed August 31, 2010
   Google Scholar
• . National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. http://www.nof.org/professionals/NOF_Clinicians_Guide.pdf. Accessed August 31, 2010
   Google Scholar
• . Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–475
   PubMed Web of Science ®Google Scholar
• . Becker DJ, Yun H, Kilgore ML, . Health services utilization after fractures: evidence from Medicare. J Gerontol A Biol Sci Med Sci. 2010;65(9):1012–1020
   PubMed Web of Science ®Google Scholar
• . National Osteoporosis Foundation. Fast facts on osteoporosis. http://www.nof.org/osteoporosis/diseasefacts.htm#top. Accessed September 8, 2009
   Google Scholar
• . Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med. 1991;151(10):2026–2032
   PubMedGoogle Scholar
• . Federal Interagency Forum on Aging-Related Statistics. Older Americans 2008: key indicators of well-being. http://www.agingstats.gov/agingstatsdotnet/main_site/data/2008_Documents/Population.aspx. Accessed March 1, 2010
   Google Scholar
• . Iacono MV. Osteoporosis: a national public health priority. J Perianesth Nurs. 2007;22(3):175–180; quiz 181–172
   PubMedGoogle Scholar
• . Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med. 2003;163(18):2165–2172
   PubMed Web of Science ®Google Scholar
• . Martens MG, Shaw H. Maximizing effectiveness of bisphosphonate therapy for osteoporosis. South Med J. 2008;101(8):824–830
   PubMed Web of Science ®Google Scholar
• . Baim S, Binkley N, Bilezikian JP, . Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008;11(1):75–91
   PubMed Web of Science ®Google Scholar
• . Kanis JA, Burlet N, Cooper C, ; European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19(4):399–428
   PubMed Web of Science ®Google Scholar
• . World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at the Primary Health Care Level: summary meeting report; Brussels, Belgium; May 5–7, 2004. http://www.who.int/chp/topics/Osteoporosis.pdf. Accessed September 24, 2010
   Google Scholar
• . National Osteoporosis Foundation. BMD testing: what the numbers mean. http://www.nof.org/osteoporosis/bmdtest.htm#Index. Accessed June 24, 2010
   Google Scholar
• . Siris ES, Miller PD, Barrett-Connor E, . Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286(22):2815–2822
   PubMed Web of Science ®Google Scholar
• . Kanis JA. FRAX®: WHO Fracture Risk Assessment Tool. http://www.sheffield.ac.uk/FRAX/. Accessed August 31, 2010
   Google Scholar
• . Kanis JA. WHO Fracture Risk Assessment Tool: FRAX® release notes. http://www.sheffield.ac.uk/FRAX/pdfs/FRAX_Release_Notes.pdf. Accessed August 31, 2010
   Google Scholar
• . Kanis JA, Oden A, Johansson H, Borgström F, Strom O, McCloskey E. FRAX® and its applications to clinical practice. Bone. 2009;44(5):734–743
   PubMed Web of Science ®Google Scholar
• . Sinaki M, Pfeifer M, Preisinger E, . The role of exercise in the treatment of osteoporosis. Curr Osteoporos Rep. 2010;8(3):138–144
   PubMedGoogle Scholar
• . Kanis JA, Borgstrom F, De Laet C, . Assessment of fracture risk. Osteoporos Int. 2005;16(6):581–589
   PubMed Web of Science ®Google Scholar
• . Tsuang YH, Sun JS, Chen LT, Sun SC, Chen SC. Direct effects of caffeine on osteoblastic cells metabolism: the possible causal effect of caffeine on the formation of osteoporosis. J Orthop Surg Res. 2006;1:7
   PubMedGoogle Scholar
• . Tinetti ME. Clinical practice. Preventing falls in elderly persons. N Engl J Med. 2003;348(1):42–49
   PubMed Web of Science ®Google Scholar
• . Cummings SR, Martin JS, McClung MR, ; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765
   PubMed Web of Science ®Google Scholar
• . Reclast [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2009
   Google Scholar
• . Boniva [package insert]. South San Francisco, CA: Genentech USA, Inc; 2010
   Google Scholar
• . Actonel [package insert]. Norwich, NY: Norwich Pharmaceuticals, Inc; 2010
   Google Scholar
• . Fosamax [package insert]. Whitehouse Station, NJ: Merck and Co, Inc; 2010
   Google Scholar
• . Bushardt RL, Turner JL, Ragucci KR, Askins DG Jr. Non-estrogen treatments for osteoporosis: an evidence-based review. JAAPA. 2006;19(12):25–30
   PubMedGoogle Scholar
• . Sontag A, Wan X, Krege JH. Benefits and risks of raloxifene by vertebral fracture status. Curr Med Res Opin. 2010;26(1):71–76
   PubMed Web of Science ®Google Scholar
• . Gilchrist N. Antiresorptive agents, raloxifene, and PHARMAC. N Z Med J. 2006;119(1230):U1885
   Google Scholar
• . Prolia [package insert]. Thousand Oaks, CA: Amgen Inc; 2010
   Google Scholar
• . Deal C. Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol. 2009;5(1):20–27
   PubMedGoogle Scholar
• . Sweet MG, Sweet JM, Jeremiah MP, Galazka SS. Diagnosis and treatment of osteoporosis. Am Fam Physician. 2009;79(3):193–200
   PubMed Web of Science ®Google Scholar
• . Bock O, Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis–optimizing efficacy in clinical practice. Clin Interv Aging. 2008;3(2):279–297
   PubMed Web of Science ®Google Scholar
• . Atelvia [package insert]. Rockaway, NJ: Warner-Chilcott; 2010
   Google Scholar
• . Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331–342
   PubMed Web of Science ®Google Scholar
• . Cole RE, Harris ST. Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application. Medscape J Med. 2009;11(1):12
   PubMedGoogle Scholar
• . Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther. 2006;28(10):1686–1694
   PubMed Web of Science ®Google Scholar
• . Emkey R, Koltun W, Beusterien K, . Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005;21(12):1895–1903
   PubMed Web of Science ®Google Scholar
• . Reginster JY, Rabenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging. 2006;1(4):415–423
   PubMed Web of Science ®Google Scholar
• . Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002;24(11):1871–1886
   PubMed Web of Science ®Google Scholar
• . Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int. 2010;21(1):145–155
   PubMed Web of Science ®Google Scholar
• . Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med. 2010;123(3):275–280
   PubMed Web of Science ®Google Scholar
• . Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther. 2008;30(4):605–621
   PubMed Web of Science ®Google Scholar
• . Cramer JA, Silverman S, Cziraky MJ, Barr CE, Poston S. Women are more persistent with monthly ibandronate vs. weekly bisphosphonates: results from a retrospective database. Value Health. 2007;10(3):A98
   PubMed Web of Science ®Google Scholar
• . Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin. 2007;23(9):2193–2203
   PubMed Web of Science ®Google Scholar
• . Lareau SC, Yawn BP. Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:401–406
   PubMedGoogle Scholar
• . Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Social Sci Med (1982). 1992;34(5):507–513
   PubMed Web of Science ®Google Scholar
• . Khosla S, Burr D, Cauley J, ; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–1491
   PubMed Web of Science ®Google Scholar
• . Pendrys DG, Silverman SL. Osteonecrosis of the jaws and bisphosphonates. Curr Osteoporos Rep. 2008;6(1):31–38
   PubMedGoogle Scholar
• . Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Int Med. 2006;144(10):753–761
   PubMed Web of Science ®Google Scholar
• . Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg. 2006;64(6):917–923
   PubMed Web of Science ®Google Scholar
• . Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res. 2009;24(4):561–574
   PubMed Web of Science ®Google Scholar
• . Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons (AAOMS). American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369–376
   PubMed Web of Science ®Google Scholar
• . American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006;137(8):1144–1150
   PubMed Web of Science ®Google Scholar
• . Schneider JP. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics. 2009;64(1):18–23
   PubMed Web of Science ®Google Scholar
• . Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22(5):346–350
   PubMed Web of Science ®Google Scholar
• . Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358(12):1304–1306
   PubMed Web of Science ®Google Scholar
• . Lee P, Seibel MJ. More on atypical fractures of the femoral diaphysis. N Engl J Med. 2008;359(3):317; author reply 317–318
   PubMedGoogle Scholar
• . Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis. N Engl J Med. 2008;359(3):316–317; author reply 317–318
   PubMed Web of Science ®Google Scholar
• . Breglia MD, Carter JD. Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy. J Clin Rheumatol. 2010;16(2):76–78
   PubMed Web of Science ®Google Scholar
• . Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24(6):1095–1102
   PubMed Web of Science ®Google Scholar
• . Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39(2):224–231
   PubMed Web of Science ®Google Scholar
• . Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008;93(8):2948–2952
   PubMed Web of Science ®Google Scholar
• . Black DM, Kelly MP, Genant HK, . Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362:1761–1771
   PubMed Web of Science ®Google Scholar
• . Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010;47(2):169–180
   PubMed Web of Science ®Google Scholar
• . Rizzoli R, Akesson K, Bouxsein M, . Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int. 2011;22(2):373–390
   PubMed Web of Science ®Google Scholar
• . Shane E, Burr D, Ebeling PR, . Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–2294
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. FDA drug safety communication: ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203891.htm. Accessed August 31, 2010
   Google Scholar
• . Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med. 2005;165(3):346–347
   PubMedGoogle Scholar
• . Bisphosphonates: bone, muscle and joint pain. Prescrire Int. 2009;18(99):23
   PubMedGoogle Scholar
• . US Food and Drug Administration. Information for healthcare professionals: bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124165.htm. Accessed August 20, 2010
   Google Scholar
• . Caplan L, Pittman CB, Zeringue AL, . An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy. Mayo Clin Proc. 2010;85(4):341–348
   PubMed Web of Science ®Google Scholar
• . Black DM, Delmas PD, Eastell R, ; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822
   PubMed Web of Science ®Google Scholar
• . Mak A, Cheung MW, Ho RC, Cheak AA, Lau CS. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet Disord. 2009;10:113
   PubMed Web of Science ®Google Scholar
• . Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf. 2009;32(3):219–228
   PubMed Web of Science ®Google Scholar
• . Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One. 2009;4(3):e4720
   Web of Science ®Google Scholar
• . Bunch TJ, Anderson JL, May HT, . Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol. 2009;103(6):824–828
   PubMed Web of Science ®Google Scholar
• . Abrahamsen B, Eiken P, Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med. 2009;265(5):581–592
   PubMed Web of Science ®Google Scholar
• . Osteoporosis drugs not linked to atrial fibrillation. Harv Heart Lett. 2009;19(8):6
   Google Scholar
• . Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168(8):826–831
   PubMedGoogle Scholar
• . Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356(18):1895–1896
   PubMed Web of Science ®Google Scholar
• . Huang WF, Tsai YW, Wen YW, Hsiao FY, Kuo KN, Tsai CR. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause. 2010;17(1):57–63
   PubMed Web of Science ®Google Scholar
• . Karam R, Camm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med. 2007;357(7):712–713; author reply 714–715
   PubMedGoogle Scholar
• . Lewiecki EM, Cooper C, Thompson E, Hartl F, Mehta D, Papapoulos SE. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract. 2010;64(6):821–826
   PubMed Web of Science ®Google Scholar
• . Black DM, Cummings SR, Karpf DB, . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535–1541
   PubMed Web of Science ®Google Scholar
• . Chesnut CH, Ettinger MP, Miller PD, . Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin. 2005;21(3):391–401
   PubMed Web of Science ®Google Scholar
• . Cummings SR, Black DM, Thompson DE, . Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077–2082
   PubMed Web of Science ®Google Scholar
• . McClung MR, Geusens P, Miller PD, ; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333–340
   PubMed Web of Science ®Google Scholar
• . Reginster J, Minne HW, Sorensen OH, . Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83–91
   PubMed Web of Science ®Google Scholar
• . Marcus R, Wong M, Heath H 3rd, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev. 2002;23(1):16–37
   PubMed Web of Science ®Google Scholar
• . McCarus DC. Fracture prevention in postmenopausal osteoporosis: a review of treatment options. Obstet Gynecol Surv. 2006;61(1):39–50
   PubMed Web of Science ®Google Scholar
• . Schnitzer T, Bone HG, Crepaldi G, . Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000;12(1):1–12
   PubMedGoogle Scholar
• . Delmas PD, Benhamou CL, Man Z, . Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int. 2008;19(7):1039–1045
   PubMed Web of Science ®Google Scholar
• . Delmas PD, McClung MR, Zanchetta JR, . Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 2008;42(1):36–42
   PubMed Web of Science ®Google Scholar
• . Eisman JA, Civitelli R, Adami S, . Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008;35(3):488–497
   PubMed Web of Science ®Google Scholar
• . Reginster JY, Adami S, Lakatos P, . Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65(5):654–661
   PubMed Web of Science ®Google Scholar
• . Watts NB, Brown JP, Cline G. Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo. J Clin Densitom. 2010;13(1):56–62
   PubMed Web of Science ®Google Scholar
• . Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008;24(1):237–245
   PubMed Web of Science ®Google Scholar
• . Cranney A, Wells GA, Yetisir E, . Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int. 2009;20(2):291–297
   PubMed Web of Science ®Google Scholar
• . MacLean C, Newberry S, Maglione M, . Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Int Med. 2008;148(3):197–213
   PubMed Web of Science ®Google Scholar
• . Recker R, Stakkestad JA, Chesnut CH 3rd, . Insufficiently dosed intravenous ibandronate injections are associated with sub-optimal antifracture efficacy in postmenopausal osteoporosis. Bone. 2004;34(5):890–899
   PubMed Web of Science ®Google Scholar
• . Miller P, Recker R, Harris ST, . Long-term fracture efficacy with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. J Bone Miner Res. 2009;24( suppl 1):Abstract A09002020
   Google Scholar
• . Bianchi G, Felsenberg D, Czerwinski E, . Efficacy of IV ibandronate is maintained over 5 years: the DIVA LTE study. Ann Rheum Dis. 2009;68( suppl 3):494
   Google Scholar
• . Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin. 2008;24(1):207–213
   PubMed Web of Science ®Google Scholar
• . Bonnick S, Saag KG, Kiel DP, . Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006;91(7):2631–2637
   PubMed Web of Science ®Google Scholar
• . Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the RisedronatE and ALendronate (REAL) cohort study. Osteoporos Int. 2007;18(1):25–34
   PubMed Web of Science ®Google Scholar
• . Harris ST, Reginster JY, Harley C, . Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone. 2009;44(5):758–765
   PubMed Web of Science ®Google Scholar
• . Curtis JR, Westfall AO, Cheng H, Saag KG, Delzell E. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int. 2009;20(6):973–978
   PubMed Web of Science ®Google Scholar
• . Bone HG, Hosking D, Devogelaer JP, ; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–1199
   PubMed Web of Science ®Google Scholar
• . Ensrud KE, Barrett-Connor EL, Schwartz A, ; Fracture Intervention Trial Long-Term Extension Research Group. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004;19(8):1259–1269
   PubMed Web of Science ®Google Scholar
• . Schwartz AV, Bauer DC, Cummings SR, ; FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX trial. J Bone Miner Res. 2010;25(5):976–982
   PubMed Web of Science ®Google Scholar
• . Sorensen OH, Crawford GM, Mulder H, . Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32(2):120–126
   PubMed Web of Science ®Google Scholar
• . Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75(6):462–468
   PubMed Web of Science ®Google Scholar
• . Watts NB, Diab DL. Long-term use of bisphosphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1555–1565
   PubMed Web of Science ®Google Scholar
• . Miller PD, Recker RR, Felsenberg D, . 5-year efficacy and safety of oral monthly ibandronate: results of the Mobile Long-Term Extension Study. Osteoporos Int. 2009;20:S199
   Web of Science ®Google Scholar
• . Devogelaer JP, Brown JP, Burckhardt P, . Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int. 2007;18(9):1211–1218
   PubMed Web of Science ®Google Scholar
• . Double-Blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis). http://clinicaltrials.gov/ct2/show/NCT00145327?term=00145327&rank=1. Accessed October 15, 2010
   Google Scholar
• . Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int. 2008;19:1613–1620
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. FDA news release: generic Fosamax approved. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116854.htm. Accessed August 31, 2010
   Google Scholar
• . Ringe JD, Möller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int. 2009;30(2):213–221
   PubMed Web of Science ®Google Scholar
• . Sheehy O, Kindundu CM, Barbeau M, LeLorier J. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int. 2009;20(8):1369–1376
   PubMed Web of Science ®Google Scholar
• . Grima DT, Papaioannou A, Airia P, Ioannidis G, Adachi JD. Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. BMC Musculoskelet Disord. 2010;11(1):68
   PubMedGoogle Scholar
• . Halkin H, Dushenat M, Silverman B, . Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother. 2007;41(1):29–34
   PubMed Web of Science ®Google Scholar
• . Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21(9):1453–1460
   PubMed Web of Science ®Google Scholar
• . Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res. 2001;16:S529–S529
   Web of Science ®Google Scholar
• . Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28(2):236–242
   PubMed Web of Science ®Google Scholar
• . Siris ES, Harris ST, Rosen CJ, . Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013–1022
   PubMed Web of Science ®Google Scholar
• . Rossini M, Bianchi G, Di Munno O, ; Treatment of Osteoporosis in Clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17(6):914–921
   PubMed Web of Science ®Google Scholar
• . Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med. 2006;119(4 suppl 1):S32–S37
   PubMed Web of Science ®Google Scholar
• . Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Manag Care Pharm. 1998;4(5):488–492
   Google Scholar
• . Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int. 2010;86(3):202–210
   Web of Science ®Google Scholar
• . Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15(12):1003–1008
   PubMed Web of Science ®Google Scholar
• . McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271–287
   PubMed Web of Science ®Google Scholar
• . Cramer JA, Roy A, Burrell A, . Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47
   PubMed Web of Science ®Google Scholar
• . Cramer JA, Silverman SL, Gold DT. Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Curr Med Res Opin. 2007;23(10):2369–2377
   PubMed Web of Science ®Google Scholar
• . Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin. 2006;22(12):2383–2391
   PubMed Web of Science ®Google Scholar
• . Cramer JA, Amonkar MM, Hebborn A, Suppapanya N. Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? Poster presented at: 26th Annual Meeting of the American Society for Bone and Mineral Research; October 1–5, 2004; Seattle, WA
   Google Scholar
• . Delmas PD, Vrijens B, Eastell R, ; Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007;92(4):1296–1304
   PubMed Web of Science ®Google Scholar
• . Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006;119(4 suppl 1):S25–S31
   PubMed Web of Science ®Google Scholar
• . Chapurlat RD, Cummings SR. Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness? Osteoporos Int. 2002;13(9):738–744
   PubMed Web of Science ®Google Scholar
• . Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(3):1117–1123
   PubMed Web of Science ®Google Scholar
• . Lekkerkerker F. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int. 2007;18( suppl 1):Abstract SY531
   PubMedGoogle Scholar
• . Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, . Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone. 2000;26(5):505–511
   PubMed Web of Science ®Google Scholar
• . Hochberg MC, Silverman SL, Barr CE, Miller PD. The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. J Clin Densitom. 13(2):181–189
   PubMed Web of Science ®Google Scholar
• . Donovan JL. Patient decision making. The missing ingredient in compliance research. Int J Technol Assess Health Care. 1995;11(3):443–455
   PubMed Web of Science ®Google Scholar
• . Lau E, Papaioannou A, Dolovich L, . Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician. 2008;54(3):394–402
   PubMed Web of Science ®Google Scholar
• . Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom. 2006;9(1):4–14
   PubMed Web of Science ®Google Scholar
• . World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129
   PubMed Web of Science ®Google Scholar